Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q9BW62

UPID:
KATL1_HUMAN

ALTERNATIVE NAMES:
p60 katanin-like 1

ALTERNATIVE UPACC:
Q9BW62; A8K5X4

BACKGROUND:
The protein Katanin p60 ATPase-containing subunit A-like 1, alternatively named p60 katanin-like 1, is instrumental in microtubule dynamics control in Sertoli cells, a key process for spermiogenesis and male fertility. It severs microtubules in an ATP-dependent manner, enabling swift reorganization of microtubule arrays, a vital process for cellular architecture and function.

THERAPEUTIC SIGNIFICANCE:
Exploring the function of Katanin p60 ATPase-containing subunit A-like 1 offers a pathway to innovative therapeutic approaches. Given its essential role in male fertility through spermiogenesis, targeting this protein could provide new solutions for treating male infertility.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.